Business
Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types
Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studies PRINCETON, N.J., March 07,
About this update from Certara, Inc.
[{"type":"text","content":"Simcyp Simulator has been utilized to inform more than 300 label claims for 90+ novel drugs in lieu of conducting clinical studies\nPRINCETON, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Simulator Version 22, which includes new capabilities and updated features to the Company’s population-based modeling and simulation platform. The Simcyp Simulator is the pharmaceutical industry’s most sophisticated physiologically based pharmacokinetics (PBPK) platform and is being applied to small and large molecule drug candidates. The Simcyp Simulator has proven use cases across drug development, including first-in-human dosing, extrapolation to special populations, bioequivalence testing, optimizing clinical study design and predicting drug-drug interactions (DDIs). “We are excited to expand and improve upon the Simcyp Simulator capabilities to advance modern drug development with the launch of our latest version,” said Masoud Jamei, Ph. D, SVP of Simcyp R&D at Certara. “These novel capabilities address a wider set of scientific analyses by expanding the range of populations, compounds, therapeutic types, and drug delivery approaches.” New capabilities in Version 22 include: Additional ethnic populations to reflect the diversity of patient types that would be prescribed new drugsExpansion of compound library allowing expedited assessment of DDIs for a wider variety of therapeutic compoundsEnhancement of subcutaneous dosing capabilities to improve bioavailability predictions after sub-cutaneous dosing of large and small moleculesUpgraded capabilities for simulating drugs PK during pregnancy, lactation, and pediatric for small and large molecule drugsExpanding and enhancing mechanistic modelling of kidney transporters, dermal absorption for new skin types, long acting injectables (LAI), excipients modelling and virtual bioequivalence, cross trials and species fitting, and mechanism-based inhibition (MBI) of metabolism. Certara also unveiled Simcyp™ Designer, an intuitive environment for users to develop Pharmacodynamic (PD) and Quantitative Systems Pharmacology (QSP) models linked to Simcyp PBPK models. Simcyp Designer is available as an add-on module to the Simcyp simulator. “Biosimulation, specifically PBPK continues to grow in regulatory adop...